Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/57976
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMatsuda K.en
dc.contributor.authorMoran L.en
dc.contributor.authorYang C.en
dc.contributor.authorMarques F.Z.en
dc.contributor.authorOkada Y.en
dc.contributor.authorNamba S.en
dc.contributor.authorVincent A.en
dc.date.accessioned2026-04-26T23:38:18Z-
dc.date.available2026-04-26T23:38:18Z-
dc.date.copyright2026-
dc.date.issued2026-03-21en
dc.identifier.citationmedRxiv. (no pagination), 2026. Date of Publication: 12 Feb 2026.-
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/57976-
dc.description.abstractBackground: Sex hormone alterations, such as estrogen deficiency or testosterone excess, substantially increase cardiovascular disease (CVD) risk in females. Dietary fibre and its microbial by-products, short-chain fatty acids (SCFAs), have cardioprotective effects, but it remains unclear whether these benefits extend to females with an altered sex hormone profile. In this study, we aim to investigate whether dietary fibre intake, measured via plasma acetate-the most abundant SCFA-is associated with improved cardiovascular outcomes in females with altered sex hormone profiles. Method(s): This cohort study included 116,235 female participants from the UK Biobank and Biobank Japan with up to 10 years of follow-up. We analysed early menopause (as a surrogate for estrogen insufficiency) and plasma free testosterone (in a subset). The primary outcome was major adverse cardiovascular events (MACE). Secondary outcomes were blood pressure. Proteomics analyses explored potential mechanisms. Result(s): Acetate levels were associated with lower 10-year MACE incidence (-0.618/1000 woman-year, HR=0.900, p=0.002) and systolic blood pressure (-0.231 mmHg per 1 SD, p<0.001) in the UK Biobank. High acetate levels attenuated the increased MACE risk associated with early menopause (HR=1.158, p=0.057) compared with low acetate (HR=1.425, p<0.001), with similar patterns replicated in Biobank Japan (high: HR=1.322, p=0.090; low: HR=1.385, p=0.042). Proteomics analyses suggested a mechanism involving pro-inflammatory proteins. Moreover, high acetate levels attenuated the increased MACE associated with elevated free testosterone in the UK Biobank (high: HR=1.238, p=0.024; low: HR=1.056, p=0.666). A significant interaction between acetate and free testosterone on systolic blood pressure indicated that the effect of rising testosterone on blunting acetate's effect (beta=0.167, 95% CI: [5.212x10-2-2.818x10-1], p=0.004) was partially mediated by central obesity (waist-to-hip ratio). Conclusion(s): Higher plasma acetate levels were associated with lower cardiovascular risk, particularly in females with early menopause or elevated free testosterone, potentially via inflammatory pathways. These findings underscore the importance of hormonal context in shaping cardiometabolic resilience and support personalised CVD prevention strategies for females with altered sex hormone profiles, including increasing dietary fibre intake.Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.-
dc.publishermedRxiv-
dc.relation.ispartofmedRxiv-
dc.titleAcetate, a fibre-derived gut metabolite, and modification of hormone-related cardiovascular risk in females.-
dc.typePreprint-
dc.identifier.affiliationMonash University - School of Biomedical Sciences-
dc.identifier.affiliationCardiology (MonashHeart)-
dc.identifier.affiliationMonash University - Monash Centre for Health Research and Implementation-
dc.identifier.doihttps://dx.doi.org/10.64898/2026.02.10.26346040-
dc.publisher.placeUnited States-
dc.identifier.institution(Yang, Marques) Hypertension Research Laboratory, Department of Pharmacology, Biomedical Discovery Institute, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia-
dc.identifier.institution-
dc.identifier.institution(Yang, Moran, Marques) Victorian Heart Institute, Monash University, Melbourne, Australia-
dc.identifier.institution-
dc.identifier.institution(Namba, Okada) Department of Genome Informatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan-
dc.identifier.institution-
dc.identifier.institution(Namba, Okada) Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan-
dc.identifier.institution-
dc.identifier.institution(Namba, Okada) Laboratory for Systems Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan-
dc.identifier.institution-
dc.identifier.institution(Matsuda) Laboratory of Clinical Genome Sequencing, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan-
dc.identifier.institution-
dc.identifier.institution(Matsuda) Laboratory of Genome Technology, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan-
dc.identifier.institution-
dc.identifier.institution(Okada) Laboratory of Statistical Immunology, Immunology Frontier Research Center (WPI-IFReC), Osaka University, Suita, Japan-
dc.identifier.institution-
dc.identifier.institution(Okada) Premium Research Institute for Human Metaverse Medicine (WPI-PRIMe), Osaka University, Suita, Japan-
dc.identifier.institution-
dc.identifier.institution(Moran, Vincent) Monash Centre for Health Research and Implementation (MCHRI), Monash University, Melbourne, Australia-
dc.identifier.institution-
dc.identifier.institution(Marques) Baker Heart and Diabetes Institute, Melbourne, Australia-
dc.identifier.affiliationmh(Yang, Marques) Hypertension Research Laboratory, Department of Pharmacology, Biomedical Discovery Institute, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia-
dc.identifier.affiliationmh-
dc.identifier.affiliationmh(Yang, Moran, Marques) Victorian Heart Institute, Monash University, Melbourne, Australia-
dc.identifier.affiliationmh-
dc.identifier.affiliationmh(Moran, Vincent) Monash Centre for Health Research and Implementation (MCHRI), Monash University, Melbourne, Australia-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairetypePreprint-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptEndocrinology-
Appears in Collections:Articles
Show simple item record

Page view(s)

28
checked on May 26, 2026

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.